Status: Ongoing, but not recruiting participants
ClinicalTrials.gov Identifier: NCT02712008
Regeneron Ruby: A randomized, double-masked active-controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of repeated doses of Intravitreal REGN910-3 in patients DME.
Condition: Diabetic Macular Edema
Study Type: Interventional
Duration: 36 weeks
Eligibility:
For additional information on this study, please click here
Back to Clinical Research